Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Abiraterone Acetate Significantly Improves Overall Survival of Patients With Post-Chemotherapy Metastatic Castration-Resistant Prostate Cancer


News provided by

Janssen Pharmaceutical

25 May, 2011, 21:00 GMT

Share this article

Share toX

Share this article

Share toX

HIGH WYCOMBE, England, May 25, 2011 /PRNewswire/ --

- Findings Published Today in The New England Journal of Medicine

A study published today in The New England Journal of Medicine in patients with metastatic advanced prostate cancer following chemotherapy who were treated with abiraterone acetate plus prednisone/prednisolone showed a significant improvement in overall survival compared to patients treated with prednisone/prednisolone plus placebo. The study was sponsored by Janssen.

The randomized, placebo-controlled Phase 3 study, COU-AA-301, evaluated whether the investigational agent abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival in patients with metastatic castration resistant prostate cancer (CRPC) - also defined as metastatic prostate cancer - whose disease had progressed following chemotherapy.

Androgens are hormones that promote the development and maintenance of male sex characteristics.[1] However, in prostate cancer, androgens can help fuel the tumour's growth.[2] Androgen production primarily occurs in the testes and adrenal glands; in men with prostate cancer, the tumour tissue is an additional source of androgens.[3] Abiraterone acetate is an oral androgen biosynthesis inhibitor that works by selectively inhibiting the CYP17 enzyme complex, which is required for the production of androgens at these three sources.[4]

After a median follow-up of 12.8 months, overall survival for the group receiving abiraterone acetate plus prednisone/prednisolone was 14.8 months vs. 10.9 months for placebo plus prednisone/prednisolone (representing a 36 percent increase in median survival). Treatment with abiraterone acetate also resulted in a 35 percent reduction in the risk of death (HR=0.646; 95 percent CI: 0.543, 0.768; p<0.0001) compared with placebo. This study included 1,195 patients with metastatic CRPC who were previously treated with one or two chemotherapy regimens, at least one of which contained docetaxel.

The study investigators stated that, overall, despite the advanced age and level of frailty in the treatment population, patients had high compliance with abiraterone acetate treatment, for which the toxicities were easily manageable and reversible.[5]

"Given that men with metastatic advanced prostate cancer have few options, we are pleased with the results of this rigorous study which show that abiraterone acetate may extend survival in these patients," said Johann S. de Bono, MD, FRCP, MSc, PhD, The Institute for Cancer Research, The Royal Marsden NHS Foundation Trust, and lead author. "The data indicate that abiraterone acetate has the potential to meet a significant unmet need for advanced prostate cancer patients and their families."

Men who received abiraterone acetate and prednisone/prednisolone also showed significant improvements in secondary study endpoints when compared to the prednisone/prednisolone plus placebo group: time to PSA progression (TTPP) [median 10.2 months for abiraterone acetate vs. 6.6 months for placebo, HR=0.580 (95 percent CI: 0.462, 0.728); p<0.0001] and an increase in radiographic progression-free survival (rPFS) [median 5.6 months for abiraterone acetate vs. 3.6 months for placebo, HR=0.673 (95 percent CI: 0.585, 0.776); p<0.0001].

Total confirmed PSA response, defined as greater than or equal to a 50 percent decrease from baseline, was achieved in 29 percent of patients treated with abiraterone acetate vs. 6 percent in the prednisone/prednisolone plus placebo group [p<0.0001].

"Prostate cancer is the fifth most common cancer globally, and is the most common cancer in men in the UK," said Dr Rob Jones, Clinical Senior Lecturer in the Institute of Cancer Sciences at the University of Glasgow. "We believe the findings of this Phase 3 study of abiraterone acetate are an important development for a patient population in need of more therapeutic solutions."

Patients in the abiraterone acetate group experienced more mineralocorticoid-related adverse events than those in the prednisone/prednisolone plus placebo group. The most common adverse events were fluid retention (31 percent vs. 22 percent), hypertension (10 percent vs. 8 percent) and hypokalemia (17 percent vs. 8 percent). Grade 3/4 hypokalemia and hypertension were more frequent in the abiraterone acetate arm than in the placebo arm (3.8 percent vs. 0.8 percent and 1.3 percent vs. 0.3 percent, respectively). Liver function test abnormalities were observed in 10 percent of abiraterone acetate-treated patients compared to 8 percent in the prednisone/prednisolone plus placebo group. Cardiac disorders were observed in 13 percent of abiraterone acetate patients vs. 10 percent of patients who received placebo.

The Independent Data Monitoring Committee recommended unblinding this Phase 3 study at interim analysis, as these results exceeded the preplanned stopping criteria. Furthermore, the IDMC recommended that patients in the prednisone/prednisolone plus placebo group be offered treatment with abiraterone acetate.

The results of this randomized, double-blind, placebo-controlled study were also presented in part during a late-breaking presentation at the Presidential Symposium at the 35th Annual European Society for Medical Oncology (ESMO) Congress in Milan, Italy on October 11, 2010.

Study Design

This randomized, double-blind placebo-controlled Phase 3 study was conducted in 147 centres in 13 countries. Patients with metastatic advanced prostate cancer previously treated with docetaxel (N=1,195) were randomly assigned 2:1 to receive abiraterone acetate (1000 mg once daily) plus prednisone/prednisolone (5 mg twice daily) (N=797), or placebo plus prednisone/prednisolone (N=398). The primary endpoint was overall survival.

About Abiraterone Acetate

Abiraterone acetate is an investigational, oral medication being developed for the treatment of men with metastatic castration resistant prostate cancer who have received prior chemotherapy containing docetaxel.

Abiraterone acetate received approval from the U.S. Food and Drug Administration (FDA) on 28 April 2011. An application is pending with the European Medicines Agency.

About Metastatic Advanced Prostate Cancer

Metastatic castration-resistant prostate cancer or CRPC occurs when cancer has metastasized beyond the prostate and disease progresses despite serum testosterone below castrate levels.[6]

The prostate is a gland located around the urethra (under the bladder) in men that produces part of the seminal fluid.[7] In some cases, cancer of the prostate can grow slowly compared with other cancers. However, depending on factors including characteristics specific to the patient and the tumour, prostate cancer also can grow very quickly and spread widely.[8]

Globally, prostate cancer is the second most frequently diagnosed cancer in men and the fifth most common cancer overall.[9] Nearly 900,000 new cases of prostate cancer were diagnosed in 2008, including 36,700 inthe UK.[10] Additionally, in 2008, more than 258,000 men died from the disease, a 16 percent increase from 2002.[11],[12]

About Janssen

The Janssen Pharmaceutical Companies are dedicated to addressing and solving the most important unmet medical needs of our time. Our people, across many different companies, are united in their passionate pursuit of science for the benefit of patients. With employees in over 50 countries, we share the commitment of our corporate parents, to bring innovative ideas, products and services to patients throughout the world.

More information can be found at http://www.janssen.co.uk

About the Ortho Biotech Oncology Research & Development, Unit of Cougar Biotechnology, Inc.

Ortho Biotech Oncology Research & Development, Unit of Cougar Biotechnology, Inc. partners with affiliated units and companies in the Janssen Pharmaceutical Companies in the research and development of oncology and supportive care treatments.

[1] National Cancer Institute. Dictionary of Cancer Terms - Androgen. Available at: http://www.cancer.gov/dictionary?CdrID=45592.

[2] American Cancer Society. Cancer Facts & Figures 2010. Atlanta: American Cancer Society; 2010.

[3] ZYTIGA (abiraterone acetate) Draft Label. November 2010.

[4] ZYTIGA (abiraterone acetate) Draft Label. November 2010.

[5] de Bono JS, Logothetis CJ, et al. Survival In Metastatic Prostate Cancer Treated with Abiraterone Acetate. New England Journal of Medicine. DRAFT MANUSCRIPT

[6] Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010 September; 17(Supplement 2): S72-S79.

[7] An Introduction to Prostate Cancer. Prostate Cancer Foundation. 2009. Available at: http://www.prostatecancerfoundation.org/atf/cf/{705B3273-F2EF-4EF6-A653-E15C5D8BB6B1}/IntroProstateCancer.pdf. Accessed November 2009.

[8] Mayo Clinic. "Prostate Cancer." http://www.mayoclinic.com/health/prostate-cancer/DS00043. Accessed September 10, 2010.

[9] GLOBOCAN 2008 (IARC). "Prostate Cancer." http://globocan.iarc.fr/factsheets/cancers/prostate.asp. Accessed August 1, 2010.

[10] GLOBOCAN 2008 (IARC). "Prostate Cancer." http://globocan.iarc.fr/factsheets/cancers/prostate.asp. Accessed August 1, 2010.

[11] GLOBOCAN 2008 (IARC). "Prostate Cancer." http://globocan.iarc.fr/factsheets/cancers/prostate.asp. Accessed August 1, 2010.

[12] Parkin, D. et al. "Global Cancer Statistics 2002." CA Cancer J Clin (2005) 55;74-108.

Modal title

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.